Denise Guevara, DO
Dermatology · Tamarac, FLNPI 1356644264
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (53.9%), other and consulting fees — rather than concentrated in one kind of arrangement. 38 manufacturers reported payments, led by Biofrontera Inc. at 44.4% of the total. 2025 is the largest year on record at $11,844, 4.4 times the $2,705 reported in 2019.
Across 563 payments — averaging $41.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biofrontera Inc.$10K
- AbbVie$2K
- UCB, Inc.$1K
- LEO Pharma Inc.$1K
- Sun Pharmaceutical Industries Inc.$930
- Incyte Corporation$719
- plus $6K from 32 others
Across 14 payments — averaging $20,033 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi Pasteur Inc.$204K
- Sun Pharmaceutical Industries Inc.$77K
What the payments were for
- Consulting fees$5903%
- Speaking & faculty fees$3502%
- Food & beverage$12,50454%
- Education$2261%
- Other$9,54841%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biofrontera Inc. | 22 | $10,320 |
| AbbVie | 120 | $2,393 |
| UCB, Inc. | 34 | $1,372 |
| LEO Pharma Inc. | 58 | $1,285 |
| Sun Pharmaceutical Industries Inc. | 35 | $930 |
| Incyte Corporation | 28 | $719 |
| Pfizer | 31 | $714 |
| Lilly USA, LLC | 20 | $682 |
| Novartis | 35 | $635 |
| E.r. Squibb & Sons, L.L.C. | 13 | $587 |
| Sanofi | 19 | $532 |
| Regeneron Healthcare Solutions, Inc. | 8 | $409 |
| VYNE Pharmaceuticals Inc. | 16 | $294 |
| Galderma Laboratories, L.p. | 17 | $286 |
| Prugen, Inc. Pharmaceuticals | 6 | $275 |
| Paratek Pharmaceuticals, Inc. | 22 | $236 |
| Mayne Pharma Commercial LLC | 13 | $230 |
| Botanix SB Inc | 2 | $146 |
| Johnson & Johnson | 6 | $142 |
| Dermavant Sciences, Inc. | 6 | $121 |
| Organon | 9 | $100 |
| Bristol Myers Squibb | 5 | $85 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 4 | $76 |
| Arcutis Biotherapeutics, Inc. | 4 | $75 |
| Strata Skin Sciences, Inc. | 5 | $71 |
| Almirall LLC | 4 | $69 |
| Amgen | 3 | $67 |
| Kerecis Limited | 2 | $55 |
| Organogenesis Inc. | 2 | $51 |
| Pierre Fabre Pharmaceuticals, Inc. | 2 | $49 |
| Helsinn Therapeutics (U.S.), Inc. | 2 | $41 |
| EPI Health, LLC | 2 | $40 |
| Encore Dermatology Inc. | 2 | $35 |
| Boehringer Ingelheim | 2 | $31 |
| DUSA Pharmaceuticals, Inc. | 1 | $18 |
| Merck | 1 | $17 |
| Bioventus LLC | 1 | $15 |
| Dermira, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$23,219 in reported general payments places this provider in the 85th percentile of 1,147 dermatology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Clobetasol Propionate | 40 | $2,565 |
| Mometasone Furoate | 90 | $1,709 |
| Imiquimod | 23 | $1,589 |
| Ivermectin | 14 | $1,551 |
| Ketoconazole | 118 | $1,359 |
| Triamcinolone Acetonide | 63 | $716 |
| Clindamycin Phosphate | 32 | $678 |
| Betamethasone Dipropionate | 18 | $603 |
| Gentamicin Sulfate | 14 | $470 |
| Mupirocin | 77 | $452 |
| Ciclopirox | 23 | $353 |
| Hydrocortisone | 51 | $258 |
| Betamethasone Valerate | 11 | $230 |
| Cephalexin | 16 | $229 |
| CiclopiroxCiclopirox Olamine | 15 | $182 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Tamarac
- Francisco KerdelMiami$2.1M
- Brad GlickMargate$2M
- Robert KirsnerMiami$1.4M
- John MinniStuart$1.4M
- Gil YosipovitchMiami$1M
- Shino Bay AguileraFt Lauderdale$1M
- Robert SnyderPembroke Pines$1M
- Marc IngleseTallahassee$989K
- Jeremy GreenCoral Gables$952K
- Mercedes GonzalezMiami$943K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.